Curated News Stories

Hand-picked stories from across the web, curated for relevance and quality.

Lantern Pharma Reports Q1 2026 Results, Cuts R&D Spending 47% and Advances AI Commercialization with Zeta.ai Launch

Lantern Pharma Reports Q1 2026 Results, Cuts R&D Spending 47% and Advances AI Commercialization with Zeta.ai Launch

Lantern Pharma reported a 47% reduction in R&D spending year-over-year, advanced key clinical programs including FDA clearance for LP-300's Phase 2 HARMONIC trial and IND approval for Starlight Therapeutics' pediatric CNS cancer program, and launched withZeta.ai, its multi-agentic AI platform, marking a shift toward AI commercialization and extended financial runway into Q1 2027.

Read full story